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MsaB and CodY Interact To Regulate Staphylococcus aureus
Capsule in a Nutrient-Dependent Manner
Justin L. Batte,a Gyan S. Sahukhal,a Mohamed O. Elasria
aDepartment of Biological Sciences, The University of Southern Mississippi, Hattiesburg, Mississippi, USA
ABSTRACT Staphylococcus aureus has a complex regulatory network for controlling
the production of capsule polysaccharide. In S. aureus, capsule production is con-
trolled by several regulators in response to various environmental stimuli. Previously,
we described MsaB as a new regulator that specifically binds to the cap promoter in
a growth phase- or nutrient-dependent manner. In addition to MsaB, several other
regulators have also been shown to bind the same region. In this study, we exam-
ined the interactions between MsaB and other nutrient-sensing regulators (CodY and
CcpE) with respect to binding to the cap promoter in a nutrient-dependent manner.
We observed that msaABCR and ccpE interact in a complex fashion to regulate cap-
sule production. However, we confirmed that ccpE does not bind cap directly. We
also defined the regulatory relationship between msaABCR and CodY. When nutri-
ents (branched-chain amino acids) are abundant, CodY binds to the promoter region
of the cap operon and represses its transcription. However, when nutrient concen-
trations decrease, MsaB, rather than CodY, binds to the cap promoter. Binding of
MsaB to the cap promoter activates transcription of the cap operon. We hypothesize
that this same mechanism may be used by S. aureus to regulate other virulence fac-
tors.
IMPORTANCE Findings from this study define the mechanism of regulation of cap-
sule production in Staphylococcus aureus. Specifically, we show that two key regula-
tors, MsaB and CodY, coordinate their functions to control the expression of capsule
in response to nutrients. S. aureus fine-tunes the production of capsule by coordinat-
ing the activity of several regulators and by sensing nutrient levels. This study dem-
onstrates the importance of incorporating multiple inputs prior to the expression of
costly virulence factors, such as capsule.
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Staphylococcus aureus is a human commensal bacterium that often asymptomaticallycolonizes the anterior nares and skin of healthy individuals. However, S. aureus is an
opportunistic pathogen that can also cause life-threating infections (1, 2). The process
by which the bacterium adapts from a commensal lifestyle to a pathogenic one is
linked to a plethora of regulatory loci of S. aureus (1–4). The fine-tuning of these
regulatory loci is necessary for the organism to alter basic metabolic processes and to
activate an arsenal of virulence factors, such as the production of capsular polysaccha-
rides, which are required for successful colonization and infection (5–8). The in vitro
expression of many of these virulence factors, including both extracellular and surface-
associated proteins, is tightly regulated to specific phases of growth. For instance, many
surface-bound proteins (i.e., fibronectin-binding protein, coagulase, and protein A) are
expressed during the exponential phase of growth, whereas many secreted proteins,
such as extracellular proteases and capsule polysaccharide, are predominantly ex-
pressed during the post-exponential phases of growth (6, 9–11). However, the envi-
ronmental factors or host factors encountered in vivo that impact the regulation of
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expressed virulence factors remain poorly understood. Recently, several nutrient-
sensing regulatory proteins have been identified as forming an important crossroad for
the switch from a commensal to a pathogenic state, a step that is essential for the
establishment of an infection (7, 12–14). This nutrient-dependent regulation is neces-
sary for the organism to adapt to and survive during the different nutrient-limiting or
stressful conditions encountered within the host during the colonization and infection
processes. The production of the capsule polysaccharide has been shown to be an
important factor in this switch from a commensal to a pathogenic form by aiding the
ability of the pathogen to survive during infection (8, 15–18). S. aureus capsule
polysaccharide has been shown to have a major role in bacterial virulence during
infection by facilitating the survival of the pathogen inside the host, primarily via acting
as an antiphagocytic factor to escape phagocytic uptake (19–21). As previously men-
tioned, in vitro capsule polysaccharide production is regulated in a growth phase-
dependent manner and is suppressed during the early and mid-exponential growth
phases and activated during the late and post-exponential growth phases (22–25).
However, our previous data, as well as those from other groups, suggest that, in
addition to growth phase, nutrient availability is also critical for the control of capsule
production (8, 22, 25–27).
S. aureus produces four main serotypes of capsule, including the heavily encapsu-
lated serotypes CP1 and CP2 and the microcapsulated serotypes CP5 and CP8. How-
ever, in the clinical context, serotypes CP5 and CP8 are considered the most significant
and are present in 70 to 80% of clinical isolates (28–30). In S. aureus, capsule production
is encoded by a single operon that contains 16 genes (31, 32). The genes that encode
the CP5 and CP8 serotypes are very similar, including serotype-specific genes that are
flanked by a nearly identical common region (33). Based on the similarities of the gene
sequences of these two serotypes, it is thought that the regulation of the two serotypes
is also similar (25, 33). The cap operons of these two serotypes have nearly identical
promoters, which are located directly upstream from the capA open reading frame
(ORF). Detailed analysis of the cap operon promoter region indicated that it is highly
regulated (31). Generally, the activity of the cap promoter correlates with capsule
polysaccharide synthesis, suggesting that regulation predominately occurs at the level
of transcription (25, 34, 35). Several regulatory proteins have been shown to bind to the
cap operon promoter region, increasing the regulatory complexity of this region. These
proteins include the two-component systems AirSR and KdpDE and the nutrient- or
stress-sensing regulatory proteins CcpE, CodY, RbsR, SpoVG, and MsaB (25, 36–41). The
complexity of this region results in capsule polysaccharide being tightly regulated in a
growth phase-dependent manner, where it is suppressed during the early and mid-
exponential growth phases and activated during the late and post-exponential growth
phases (22–25).
In our previous studies, we have shown that deletion of themsaABCR operon and/or
msaB alone reduced cap transcription, as well as the production of capsule (25). We
have also observed that when we delete msaB, it can only be complemented by the
complete msaABCR operon, thus suggesting that the intact msaABCR operon is needed
for the expression and/or function of msaB (25). Additionally, we have shown that the
MsaB protein, a product of the msaABCR operon, binds a 10-bp regulatory repeat
located directly upstream from the cap promoter and activates capsule production (25).
We found that MsaB only binds to the cap promoter region during the late and
post-exponential phases of growth under nutrient-rich growth conditions, even though
MsaB is present throughout all growth phases. However, when the nutrient concen-
trations are altered, the binding ability of MsaB changes, which leads to observable
changes in the expression of the cap transcript, as well as the production of capsule
polysaccharide. This indicates that nutrients are important for the regulatory interaction
of MsaB in binding to and activating the cap promoter (25). This led us to hypothesize
that the binding ability of MsaB may be altered by changes in nutrient concentrations
or that the MsaB binding site may be masked by other regulatory proteins under these
conditions. Two nutrient-sensing regulatory proteins, CodY and CcpE (catabolite con-
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trol protein E), have been shown to bind to the cap promoter region as repressors of
cap production (37, 39). In this study, we show that complex regulatory interactions are
present between MsaB and the other nutrient-dependent cap regulators, CodY and
CcpE. We observed that nutrient concentrations influence the binding capability of
these regulators within the cap promoter region. Interestingly, we observed that not
only do these regulators control the cap promoter region, but the MsaB, CodY, and
CcpE regulators appear to be responsible for the transcriptional regulatory control of
each other’s genes in complex and incoherent feed-forward loops. We found that
mutation of any of these regulators differentially alters the transcription of genes of the
other regulators, as well as the cap transcript, further demonstrating the tight regulatory
control of cap. The interactions between these putative global regulatory proteins seem to
lie at the crossroad between basic metabolic processes and the coordinated control of the
production of virulence factors required for the bacterium to establish infection.
RESULTS
MsaB, CodY, and CcpE coordinately regulate transcription of cap promoter
activity and, therefore, capsule production. In this study, we further investigated the
nutrient-dependent regulation of capsule production by MsaB. We examined interac-
tions between these DNA-binding cap regulators and MsaB. We tested whether mu-
tating the msaABCR operon had any regulatory effect on the known DNA-binding
regulators of cap, including AirSR, CcpE, CodY, KdpDE, RbsR, and SpoVG, in the
mid-exponential growth phase. Interestingly, we found that the msaABCR operon
mutation resulted in a change in the transcriptional regulation of both of the nutrient-
responsive regulators ccpE (upregulated) and codY (downregulated). However, no
regulatory changes were observed for any of the other regulators of cap, suggesting
that no direct regulatory interactions occur between msaABCR and these regulators
(Table 1). Thus, for this study, we focused on the nutrient-dependent regulators CodY
and CcpE to determine how they may interact with MsaB to coordinately control cap
and, ultimately, capsule production in response to nutrient stimuli.
To examine the nutrient-dependent regulatory mechanism of the cap operon, we
generated individual and double mutants with codY, ccpE, codY msaABCR, and ccpE
msaABCR mutations. We compared the cap transcripts, as well as total capsule produc-
tion, of these mutants to those of the msaABCR deletion mutant, the wild-type strain
UAMS-1, and the msaABCR complementation strain. We found that individual deletion
of msaABCR, codY, or ccpE results in differential levels of cap transcription in the
post-exponential growth phase (by 23.4-fold, 5.4-fold, and 10.3-fold, respectively)
(Table 2). This confirmed that all three regulators contribute to the transcription of the
cap operon. Deletion of the msaABCR operon had the largest effect on cap transcrip-
tion. This confirms our previous finding that deletion of the msaABCR operon leads to
decreased cap gene expression, resulting in capsule production being abolished (25).
Next, we measured the total capsule production in the codY individual mutant, as well
as in the double mutant, and compared it to the capsule production level of the
wild-type strain. In the codY mutant, we observed an increase in capsule production in
TABLE 1 Expression of cap-binding genes in the msaABCR mutant relative to their
expression in the wild-type strain
Gene Mean fold change  SEa
airR 1.25 0.04
airS 2.25 0.29
ccpE 50
codY 3.21 0.26
kdpD 1.26 0.08
kdpE 1.24 0.14
rbsR 1.86 0.13
spoVG 1.51 0.11
aGenes with a pronounced fold change value equal to or greater than 3.0 (shaded) were marked for
further study. Results are representative of at least three independent experiments for each sample set.
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the post-exponential growth phase, when capsule is maximally produced, thus con-
firming the role of CodY as a repressor of capsule production (Fig. 1A). These results
suggest that CodY negatively regulates capsule production at the posttranscriptional
level, possibly via CodY’s regulatory effect on other global regulators, such as the Agr
system (37, 42). With respect to the msaABCR codY double mutant, we observed that
the double mutation resulted in capsule production being undetectable (Fig. 1A). This
shows that MsaB is essential for the expression and production of capsule even in the
absence of repression by CodY. As mentioned above, we found that mutation of ccpE
resulted in downregulation of cap transcription, suggesting that CcpE possibly func-
tions as an activator of cap (Table 2). The mutation of ccpE alone resulted in a decrease
in total capsule production compared to the level in the wild-type strain, although
there were still detectable levels of capsule (Fig. 1B). Additionally, we compared the
capsule production phenotype of the double mutant to those of the single ccpE and
msaABCR mutants to confirm their roles in capsule production. Interestingly, we
observed that in the ccpE msaABCR double mutant, capsule production was detectable
at a level similar to that in the ccpE individual mutant (Fig. 1B). These results suggested
that ccpE may be epistatic to msaB. This is the first evidence of any detectable level of
capsule production in any of themsaABCR individual or double mutants. These findings
suggest that the double mutation of ccpE msaABCR likely affects other unknown cap
regulators, resulting in the observed basal level of capsule production. However, further
experiments are needed to investigate this possibility.
TABLE 2 Expression of capE in mutants relative to its expression in the wild-type strain
Mutation(s)
Fold change in capE expression of mutant relative to that of wild-type (mean  SE) in indicated
exponential growth stagea
Early Mid- Late Post-
msaABCR 1.645 0.03 3.925 0.09 12.53 1.29 23.41 1.79
msaABCR complement 1.08 0.01 1.12 0.04 1.07 0.02 1.18 0.06
codY 2.715 0.81 3.51 0.94 5.515 1.24 4.415 1.11
codY complement 1.18 0.03 1.23 0.09 1.24 0.07 1.16 0.12
ccpE 2.925 0.96 3.92 1.02 3.08 0.89 10.33 1.46
ccpE complement 1.02 0.08 1.03 0.09 1.01 0.02 1.13 0.05
aFold change values equal to or greater than 3.0 are considered to show pronounced differential gene expression. Results are representative of at least three
independent experiments for each sample set.
FIG 1 Mutation of codY results in more total capsule production, but mutation of ccpE results in less total capsule production. Capsule
production was assessed in wild-type (WT) UAMS-1 and the respective individual and double mutants with msaABCR (A and B), codY
(A), and ccpE (B) mutations. Samples were serially diluted as indicated and dot blotted directly onto the membrane. The blots were
processed using capsule polysaccharide (CP)-specific antibodies. Results are representative of three independent experiments for each
sample set.
Batte et al. Journal of Bacteriology
September 2018 Volume 200 Issue 17 e00294-18 jb.asm.org 4
MsaB directly controls the transcription of both codY and ccpE. To acquire a
more comprehensive understanding of the observed coordinated regulation between
MsaB, CodY, and CcpE with respect to the regulation of cap, we tested whether the
mutation of the msaABCR operon had a regulatory effect on codY or ccpE transcription.
First, we compared the absolute transcript level of codY in the msaABCR deletion
mutant to those of the wild-type UAMS-1 and the msaABCR complementation strains.
We found that the deletion of the msaABCR operon resulted in a significant downregu-
lation of codY transcripts in the late and post-exponential growth phases (Fig. 2A).
To determine whether MsaB regulates codY transcription directly, we tested the
binding of MsaB to the codY promoters using a chromatin immunoprecipitation (ChIP)
assay. Briefly, codY has two putative promoter regions: one promotes the expression of
the xerC-clpQY-codY operon, and the other promotes the expression of a 1.4-kb product
that contains the codY ORF, the latter of which is responsible for producing the codY
transcript alone (43). We tested for MsaB binding to both putative promoter regions.
Interestingly, we found that MsaB binds to both putative promoters during late and
post-exponential growth phases but not during early or mid-exponential growth
phases (Fig. 2B). Taken together, these results show that MsaB directly regulates both
the xerC-clpQY-codY operon and the 1.4-kb transcript containing the codY ORF in a
growth phase-dependent manner. These results suggest that, in addition to binding to
and activating cap in the late and post-exponential phases of growth, MsaB also
regulates the cap repressor CodY in a growth-dependent manner. The results of this
experiment show that MsaB has very tight and multidimensional regulation of the cap
promoter.
To investigate the regulatory control exerted by the msaABCR operon on CcpE, we
compared the absolute transcript level of ccpE in the msaABCR deletion mutant to the
levels in the wild-type UAMS-1 and msaABCR complementation strains. We found that
the deletion of the msaABCR operon resulted in a significant upregulation of ccpE
transcripts during all growth phases of S. aureus strain UAMS-1 (Fig. 3A). CcpE has also
been shown to regulate capsule production in S. aureus. However, there have been
contradicting reports on the role or mechanism of this regulation. Ding and colleagues
described ccpE as a direct binder of the cap operon, having a repressor role (39).
Conversely, ccpE has also been described as promoting capsule formation in S. aureus
(44). However, this regulation was found to be nondirect, as it was observed that ccpE
FIG 2 msaABCR regulates codY growth phase dependently. (A) Absolute quantification of codY in the four growth phases. Amplicons of codY were converted
to copies per microliter and then serially diluted and used as templates for RT-qPCR. Bars represent standard errors. Asterisks indicate the P value cutoff as
follows: ***, P  0.001. (B) Chromatin immunoprecipitation (ChIP) using an anti-MsaB antibody was performed to determine whether the putative promoter
regions of codY bind to MsaB from whole-cell extracts of strains in different growth phases (early, mid-, late, and post-exponential phases). Lanes are labeled
as follows: WT, whole-cell extract from the wild-type strain and anti-MsaB antibody; ΔmsaABCR, negative control, representing the whole-cell extract from the
msaABCR deletion mutant and anti-MsaB antibody; () Control, PCR product amplified from the genomic DNA of UAMS-1. These results are representative of
three independently treated samples.
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did not bind cap (44). In our study, we found the ccpE mutant exhibited a decrease in
cap transcripts, as well as total capsule production, suggesting that CcpE is an activator
of cap transcription and capsule production.
To determine whether MsaB directly regulates ccpE to induce the strong regulatory
effect observed by mutation of the msaABCR operon in UAMS-1, we tested whether
MsaB could bind to a putative promoter region upstream from the ccpE ORF using ChIP.
We observed that MsaB bound to the putative promoter region of ccpE during all
phases of growth (Fig. 3B). These results suggest that MsaB directly regulates ccpE as a
strong repressor of ccpE transcription. Taken together, these results suggest that MsaB
has an important role in regulating CodY and CcpE, which in turn are involved in the
overall nutrient-dependent regulation of cap transcription and capsule production in S.
aureus.
CodY and CcpE both regulate msaB transcription and/or MsaB’s DNA-binding
ability. In an effort to gain a comprehensive understanding of the regulatory interac-
tions between MsaB, CodY, and CcpE and determine how they regulate the cap
transcript and, ultimately, capsule production, we also tested whether either the codY
or the ccpE mutation had any regulatory impact on MsaB. First, the transcription of
msaB in the codY or ccpE mutant was measured during all phases of growth using
real-time quantitative PCR (RT-qPCR). Interestingly, we found that the mutation of
either codY or ccpE decreased msaB expression (Table 3). This was particularly evident
in the early, late, and post-exponential phases of growth, with little effect observed in
the mid-exponential growth phase. We observed that the mutation of either gene (codY
FIG 3 msaABCR regulates ccpE in all phases of growth. (A) Absolute quantification of ccpE in the four growth phases. Amplicons of ccpEwere converted to copies
per microliter and then serially diluted and used as templates for RT-qPCR. Bars represent standard errors. Student’s unpaired t test was used to compare the
results for the wild type and the respective mutants. Asterisks indicate the P value cutoff as follows: ***, P  0.001. (B) Chromatin immunoprecipitation (ChIP)
using an anti-MsaB antibody was performed to determine whether the putative promoter region of ccpE binds to MsaB from whole-cell extracts of strains in
different growth phases (early, mid-, late, and post-exponential phases). Lanes are labeled as follows: WT, whole-cell extract from the wild-type strain and
anti-MsaB antibody; ΔmsaABCR, negative control, representing the whole-cell extract from the msaABCR deletion mutant and anti-MsaB antibody; () Control,
PCR product amplified from the genomic DNA of UAMS-1. These results are representative of three independently treated samples.
TABLE 3 Expression of msaB in mutants relative to its expression in the wild-type strain
Mutation
Fold change in msaB expression of mutant relative to that of wild type (mean  SE) in indicated
exponential growth stagea
Early Mid- Late Post-
ΔcodY 2.38 0.54 1.525 0.09 3.31 0.27 3.31 0.39
codY complement 1.12 0.02 1.01 0.07 1.02 0.04 1.07 0.09
ΔccpE 3.265 0.39 1.505 0.06 2.76 0.26 5.955 0.94
ccpE complement 1.21 0.04 1.08 0.07 1.11 0.09 1.23 0.02
aFold change values equal to or greater than 3.0 were considered to show pronounced differential gene expression. Results are representative of at least three
independent experiments for each sample set.
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or ccpE) had the greatest regulatory effect on the amount of msaB transcript produced
during the late and post-exponential phases of growth. Importantly, this is when the
regulatory activity of MsaB is the most evident, as it specifically activates cap transcrip-
tion during these growth phases. These results suggest that complex regulatory
interactions occur between MsaB, CodY, and CcpE and that these regulatory interac-
tions are necessary for the tight control of capsule production.
To investigate the putatively nutrient-dependent binding of CodY or CcpE to the
cap promoter, we used constructs labeled with histidine at the 5= end that are
controlled by their native promoters to preserve complex regulation for complemen-
tation assays (5= 6His-codY or 5= 6His-ccpE, respectively). These constructs were
transformed into the codY or ccpE mutant, respectively, for trans complementation and
were used to measure the binding of CodY or CcpE via the ChIP assay. Using these
constructs, we observed that under nutrient-rich conditions, CodY bound to the cap
promoter during the early, mid-, and late exponential growth phases but not during the
post-exponential growth phase (Fig. 4A), consistent with other studies that have
examined CodY regulatory activity (13, 37, 45). We have previously observed that under
nutrient-rich conditions (tryptic soy broth [TSB]), MsaB binds to and activates the cap
promoter during late and post-exponential growth phases but not during early or
mid-exponential phases. These observations suggest that when CodY is bound to the
cap promoter under nutrient-rich conditions during early, mid-, and late exponential
phases, the MsaB binding site may not be accessible for MsaB to bind to the cap
promoter region. Additionally, we also observed that if we altered nutrient concentra-
tions in the medium, the MsaB binding ability during these phases was altered,
suggesting that a nutrient-dependent interaction is present (25).
To determine whether CodY binding alters MsaB binding to the cap promoter in a
growth phase-dependent manner, we studied MsaB binding activity in the codY
mutant. We used ChIP to determine whether the mutation of codY alters MsaB binding
FIG 4 CodY binds to cap promoters in early, mid-, and late exponential growth phases, but CcpE does not bind to cap promoters in any phase of growth in
UAMS-1 strain. Chromatin immunoprecipitation (ChIP) using an anti-His antibody was performed to determine whether the cap promoter region binds CodY
(A) or CcpE (B) from whole-cell extracts of strains in different growth phases (early, mid-, late, and post-exponential phases). 6His-codY and 6His-ccpE
complementation vectors were used to complement codY or ccpE in the respective individual mutant, as well as in the codY msaABCR or ccpE msaABCR double
mutant strain. Lanes are labeled as follows: WT, negative control, representing whole-cell extract from the wild-type strain and anti-His antibody; ΔcodY or
ΔccpE, negative control, representing whole-cell extract from the codY or ccpE deletion mutant and anti-His antibody; ΔcodY ΔmsaABCR or ΔccpE ΔmsaABCR,
negative control, representing whole-cell extract from the codY msaABCR or ccpE msaABCR double mutant and anti-His antibody; ΔcodY or ΔccpE 6His-
complement, whole-cell extract from the codY or ccpEmutant complemented with 6His-codY or 6His-ccpE and anti-His antibody; ΔcodY ΔmsaABCR or ΔccpE
ΔmsaABCR 6His-complement, whole-cell extract from the codY msaABCR or ccpE msaABCR double mutant complemented with 6His-codY or 6His-ccpE and
anti-His antibody; () Control, PCR product amplified from the genomic DNA of UAMS-1. These results are representative of triplicate independently treated
samples.
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under these nutrient-rich growing conditions. Interestingly, we found that when codY
is mutated, MsaB binds to the cap promoter during all phases of growth, including the
early and mid-exponential phases (Fig. 5A). Next, we tested whether this observed
MsaB binding in the codY mutant led directly to capsule production. We observed
detectable amounts of capsule in the codY mutant during both the early and mid-
exponential growth phases (Fig. 5B and C). These results suggest that, through an
undetermined mechanism, the binding of CodY to the cap promoter inhibits or blocks
MsaB binding to cap. However, when CodY is not bound or is not present (mutation),
MsaB can directly bind to and activate cap, leading to capsule production.
Interestingly, we found no evidence of CcpE binding to the cap promoter region
during any phase of growth (Fig. 4B). This is consistent with the study by Hartmann et
al., which found no evidence of CcpE binding to the cap promoter (44), but inconsistent
with the study by Ding et al. (39). Additionally, mutation of ccpE did not appear to have
any effect on the ability of MsaB to bind to the cap promoter (Fig. 5A). These results
suggest that CcpE regulates cap indirectly through an undetermined mechanism and
that CcpE does not have any effect on MsaB binding to the cap promoter.
MsaB and CodY interact with the cap promoter region in a nutrient-dependent
manner. Capsule production has been shown to be largely regulated by environmental
nutrient conditions. With respect to the regulatory function of CodY, when nutrient
levels are high, capsule production is repressed by CodY binding to the cap promoter.
However, when nutrient concentrations begin to decline, CodY undergoes a confor-
mational change that results in CodY not binding to its DNA targets (46, 47). Moreover,
FIG 5 CodY alters the binding ability of MsaB in early/mid-exponential growth phases and capsule is detectable in early and mid-exponential growth phases
in codY mutants. (A) Chromatin immunoprecipitation (ChIP) using anti-MsaB antibody was performed to determine whether the mutation of codY or ccpE alters
binding of the promoter region of cap to MsaB from whole-cell extracts of strains in different growth phases (early, mid-, late, and post-exponential phases)
compared to the results for wild-type UAMS-1. Lanes are labeled as follows: WT, whole-cell extract from the wild-type strain and anti-MsaB antibody; ΔmsaABCR,
negative control, representing the whole-cell extract from the msaABCR deletion mutant and anti-MsaB antibody; ΔcodY, whole-cell extract from the codY
mutant and anti-MsaB antibody; ΔccpE, whole-cell extract from the ccpE mutant and anti-MsaB antibody; () Control, PCR product amplified from the genomic
DNA of UAMS-1. (B and C) Total capsule polysaccharide (CP) production was assessed in wild-type UAMS-1 and the respective mutants with msaABCR, codY,
and msaABCR codY mutations in early exponential (B) and mid-exponential (C) phases. These results are representative of triplicate independently treated
samples.
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CodY senses the availability of nutrients, specifically GTP and branched-chain amino
acids (BCAAs), for its regulatory function (48–51). Previously, we used the prediction
tool NsitePred to analyze the MsaB sequence and found that MsaB contains predicted
nutrient-sensing domains (15 phenylalanine, 29 histidine, and 30 phenylalanine resi-
dues) for nucleotides, including GTP, ADP, and AMP, respectively (data not shown). To
explore how the interactions between MsaB, CodY, and the cap promoter may be
mediated by nutrients, we used a chemically defined medium (CDM) as a nutrient-
defined medium to determine how codY, msaB, and ultimately, cap are affected by the
presence or absence of BCAAs. We found that shifting cells from growth in CDM with
BCAAs to growth in CDM without BCAAs resulted in the upregulation of cap in the
wild-type strain (3.69-fold), resulting in more total capsule production. Under the same
conditions in the wild-type strain, msaB transcripts were upregulated (3.47-fold) but
codY and ccpE transcripts were both unaltered (Fig. 6). These results suggest that the
bacterium senses this nutrient limitation and increases transcription of msaB, which in
turn increases cap as a response to the nutrient-depleted conditions. However, it is also
possible that in the absence of the BCAAs, capsule is depressed by CodY due to its
reduction in activity. The mechanism for this process is still unknown.
Previous studies have shown that BCAA concentrations control CodY’s binding
affinity for its targets (13, 46, 47, 52). Using CDM, we tested how the presence or
absence of BCAAs affects the cap promoter binding activity of CodY. We found that
under chemically defined growth conditions in CDM with BCAAs, CodY was bound to
the cap promoter during early and mid-exponential but not late or post-exponential
growth phases. However, in cells shifted from CDM with BCAAs to CDM without BCAAs,
CodY did not bind to the cap promoter during any phase of growth (Fig. 7). Given this
nutrient-dependent binding of CodY, we hypothesized that the binding ability of MsaB
may be altered by the binding of CodY under different nutrient conditions. Addition-
ally, we used CDM with BCAAs and CDM without BCAAs to determine whether the cap
promoter binding ability of MsaB during the mid-exponential phase of growth is
dependent on CodY binding. Surprisingly, the binding activity of CodY in the presence
or absence of BCAAs did not seem to have any effect on the ability of MsaB to bind to
cap under these nutrient-defined conditions (Fig. 8A). This suggests that the ability of
MsaB to bind to cap is not dependent on BCAAs or the CodY binding activity alone.
Additionally, we also tested the ability of MsaB to bind to the cap promoter during all
phases of growth under nutrient-defined conditions. We observed that under these
conditions, MsaB bound to the cap promoter during all phases of growth (Fig. 8B).
FIG 6 msaB and capE are both upregulated in strains grown in CDM without BCAAs versus CDM with
branched-chain amino acids (BCAAs). RT-qPCR was used to measure the relative fold changes in the
expression of capE, msaB, codY, and ccpE in mid-exponential growth phase in strains subjected to CDM
with no BCAAs compared to their expression in the wild-type UAMS-1 strain grown in whole CDM. These
results are representative of at least three independent experiments for each sample set.
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These findings, in addition to those described above, suggest that the ability of MsaB
to bind to the cap promoter is altered by the binding ability of CodY under nutrient-rich
conditions. However, under nutrient-defined conditions, MsaB is able to bind cap
independently of CodY’s binding activity.
FIG 7 codY binds to cap promoter in strains grown in CDM with BCAAs but not in CDM without BCAAs. Chromatin immunoprecipitation (ChIP) using an anti-His
antibody was performed to determine whether the cap promoter region binds CodY from whole-cell extracts grown under nutrient-defined conditions of CDM
with BCAAs versus CDM without BCAAs in different growth phases (early, mid-, late, and post-exponential phases). The 6His-codY complementation vector
was used to complement codY in the codY mutant, as well as in the codY msaABCR double mutant strain. Lanes are labeled as follows: CDM (BCAAs),
chemically defined medium with BCAAs; CDM (–BCAAs), chemically defined medium without BCAAs; WT, negative control, representing whole-cell extract from
the wild-type strain and anti-His antibody; ΔcodY, negative control, representing whole-cell extract from the codY deletion mutant and anti-His antibody; ΔcodY
ΔmsaABCR, negative control, representing whole-cell extract from the codY msaABCR double mutant and anti-His antibody; ΔcodY 6His-complement,
whole-cell extract from the codY mutant complemented with 6His-codY and anti-His antibody; ΔcodY ΔmsaABCR 6His-complement, whole-cell extract from
the codY msaABCR double mutant complemented with 6His-codY and anti-His antibody; () Control, PCR product amplified from the genomic DNA of
UAMS-1. These results are representative of triplicate independently treated samples.
FIG 8 MsaB binds to the cap promoter under nutrient-defined conditions in all phases of growth. Chromatin
immunoprecipitation (ChIP) using an anti-MsaB antibody was performed to determine whether the promoter
region of the cap operon binds to MsaB from whole-cell extracts of strain grown under nutrient-defined conditions
of CDM with BCAAs versus CDM without BCAAs in the mid-exponential phase of growth (A) or in CDM with BCAAs
in different growth phases (early, mid-, late, and post-exponential phases) (B). Lanes are labeled as follows: CDM
(BCAAs), chemically defined medium with BCAAs; CDM (–BCAAs), chemically defined medium with no branched-
chain amino acids; Early, Mid, Late, and Post, whole-cell extracts from strains in the respective growth phase when
grown in whole CDM; WT, whole-cell extract from the wild-type strain and anti-MsaB antibody; ΔmsaABCR, negative
control, representing the whole-cell extract from the msaABCR deletion mutant and anti-MsaB antibody; ΔcodY,
whole-cell extract from the codY mutant strain and anti-MsaB antibody; ΔccpE, whole-cell extract from the ccpE
mutant strain and anti-MsaB antibody; () Control, PCR product amplified from the genomic DNA of UAMS-1.
These results are representative of triplicate independently treated samples.
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Given the nutrient-dependent regulation of cap and msaB transcription, as well as
the observed changes in the ability of MsaB to bind cap under these nutrient-defined
conditions, we tested the total capsule production under nutrient-defined growth
conditions. We compared the wild-type strain to themsaABCR, codY, andmsaABCR codY
mutants grown in CDM with BCAAs or in cells shifted to CDM without BCAAs. As
mentioned above, we observed upregulation of the cap and msaB transcripts in the
wild-type UAMS-1 strain in CDM without BCAAs relative to their levels in CDM with
BCAAs (Fig. 6). This correlated with an increase in total capsule production (Fig. 9A). To
confirm these findings, we quantified the intensities of the blots using ImageJ software
analysis. We found a significant increase (approximately 50%) in the total intensity of
the blots in cells shifted to CDM without BCAAs compared to that in cells grown in CDM
with BCAAs (Fig. 9B). Interestingly, under the conditions tested, no capsule production
was detected in the codY mutant, which was different from the observed result under
the nutrient-rich conditions (TSB). As a result of these findings, we tested the total
capsule production under these nutrient-depleted conditions during the late exponen-
tial phase of growth. We observed that capsule production was detectable in the codY
mutant during the late exponential phase of growth under nutrient-depleted condi-
tions (Fig. 9C). These results suggest that the observed binding of MsaB in the codY
mutant may not be sufficient to lead to capsule being produced or that the mutation
FIG 9 Total capsule production is increased in WT grown in CDM without BCAAs versus CDM with BCAAs. (A) Total capsule polysaccharide (CP)
production was assessed in wild-type UAMS-1 and the respective msaABCR and codY mutants, along with the msaABCR codY double mutant, to
compare CP production in CDM with BCAAs versus CDM with no BCAAs in the mid-exponential growth phase. (B) Image analysis of total CP
production in the wild-type UAMS-1 grown in CDM with BCAAs versus CDM with no BCAAs was performed using the ImageJ analysis software.
Results are represented as the average percentage of total coverage area of the respective blots. Student’s unpaired t test was used to compare
the results for the wild type to the results for the respective mutants. ***, P  0.001. (C) Total CP production was assessed in wild-type UAMS-1
and the respective msaABCR and codY mutants, along with the msaABCR codY double mutant, to compare the levels of CP production in CDM
with BCAAs in the late exponential growth phase. These results are representative of triplicate independently treated samples.
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of codY affects an unknown cap regulator under these nutrient-defined conditions.
However, when the cells transition from mid-exponential growth to late exponential
growth, MsaB binding becomes sufficient to directly activate the production of capsule
via an unknown mechanism. Taken together, these results show that MsaB and CodY
are both responsible for the complex temporal regulation and production of capsule in
response to nutrients and/or growth phase. Further studies are needed to fully under-
stand this complex nutrient-dependent and/or growth phase-dependent regulatory
mechanism.
DISCUSSION
Capsule polysaccharide is a well-characterized virulence factor of S. aureus and is
involved in the evasion of phagocytic uptake during certain types of infections (8). The
regulation of capsule production in S. aureus is very complex and involves several
global regulators that tightly control the expression of cap, predominately at the
transcriptional level (25, 36–41). The complexity of this regulation enables the patho-
gen to fine-tune capsule expression based on environmental or host-specific signals,
including nutrients and other stress-related factors (8, 45). We have previously identi-
fied MsaB, of themsaABCR operon, as a DNA-binding transcriptional activator of the cap
operon promoter. Interestingly, the binding of MsaB seemed to be either growth phase
dependent or mediated in a nutrient-dependent manner (25). In this study, we dem-
onstrated that, in addition to directly regulating cap, themsaABCR operon (MsaB) is also
involved in regulating two other major nutrient-dependent regulators of cap, CodY and
CcpE. The findings of this study suggest that MsaB has dual regulatory roles as a
transcriptional activator of both cap and codY and as a repressor of ccpE.
CodY has been described as a key nutrient-dependent global regulator (transcrip-
tional repressor) that not only directly regulates cap but also directly controls many
metabolic and virulence factors in S. aureus (7, 13, 37, 42, 43, 45, 53, 54). Pohl and
colleagues described CodY’s regulation of capsule in detail (43). CodY senses GTP and
BCAA concentrations within the growth environment of the bacterium. The presence or
absence of these nutrients results in a conformational change within the CodY protein
structure (46, 47, 52). This conformational change of the protein results in a decrease
in the DNA-binding affinity of CodY for its targets under conditions of low nutrient
concentrations (43, 48, 49, 51). CodY is part of a four-gene operon that produces a large,
4.1-kb transcript (43). As described previously (43), this operon is composed of the
genes xerC, clpQ, clpY, and codY. The xerC gene is thought to encode a tyrosine
recombinase, and clpQY codes for the ATP-dependent heat shock protease HslVU (55).
Within this operon, codY can be transcribed by itself as a shorter transcript that invades
the 3= end of the clpY gene, producing a 1.4-kb transcript containing the codY ORF (43).
Importantly, to the best of our knowledge, no other gene has been identified as directly
regulating codY transcription in S. aureus. In addition to MsaB directly regulating codY,
we also showed that MsaB and CodY putatively compete for binding sites within the
cap promoter region in a growth phase- or nutrient-dependent manner. We observed
that in the codY mutant, MsaB binding is altered, resulting in MsaB binding to the cap
promoter during all phases of growth under nutrient-rich conditions. This binding of
MsaB led directly to the activation of cap and resulted in capsule production during
early and mid-exponential phases. However, when CodY was present in the wild-type
strain, MsaB did not bind to the cap promoter under these same growth conditions,
resulting in no detectable capsule production.
Many studies have described nutrients as an important factor that facilitates capsule
production within different environmental niches of S. aureus (8, 22, 26, 27). Based on
the findings of this study, we suggest that the described nutrient-dependent binding
activities of MsaB and CodY lead directly to capsule production. When nutrient con-
centrations are altered, specifically in CDM in the presence or absence of BCAAs, the
transcription of msaB and cap is upregulated and the ability of MsaB to bind to the cap
promoter is altered, resulting in MsaB binding during all phases of growth. This binding
of MsaB under nutrient-defined conditions results in capsule being produced abun-
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dantly during mid-exponential growth phase, suggesting that the binding of MsaB
under nutrient-defined conditions leads directly to capsule production. It is unclear why
MsaB binds to the cap promoter during all growth phases under nutrient-defined
conditions, whereas under nutrient-rich conditions, it only binds the cap promoter
during late and post-exponential phases. This suggests that factors other than nutrients
may be involved in the binding behavior of MsaB. Additionally, under these same
nutrient-defined conditions, there was no capsule production detected in the codY
mutant (no cap repression) in CDM with BCAAs or CDM without BCAAs. This suggests
that, even though MsaB binds under these conditions, the level of binding may not be
sufficient to completely activate cap transcription or the mutation of codY alters
another cap regulator under these nutrient-depleted conditions that leads to the
inhibition of cap production. Taken together, these results suggest that MsaB may be
responding directly to the concentration of nutrients, resulting in an increase in its
ability to bind to the cap promoter, and that under chemically modified growth
conditions, the binding ability of MsaB is independent of CodY activity. Indeed, based
on amino acid sequence analysis, MsaB appears to contain nutrient (nucleotide)
binding regions, including GTP, ADP, and AMP, suggesting that it may directly bind and
respond to nucleotide or nutrient molecules.
Previously, there have been conflicting reports on the regulatory role of CcpE with
respect to cap regulation. As mentioned above, Ding et al. described ccpE as a direct
repressor of the cap operon (39). However, Hartmann et al. described ccpE as promoting
capsule formation in S. aureus but described CcpE as not binding directly to the cap
promoter (39, 44). In our study, we observed that ccpE promotes capsule formation.
However, under the conditions tested, we did not find any evidence of CcpE binding
directly to the cap promoter, suggesting that the regulatory effect of CcpE with respect
to cap is not direct and may be dependent upon another cap regulator. Importantly, in
the ccpE mutant during the post-exponential growth phase msaB (cap activator) was
also downregulated (6.0-fold). These results suggest that the observed effect on
capsule production resulting from the mutation of ccpE may be dependent on the
regulatory effect that the mutation has on the msaB transcript under these conditions.
Additionally, another interesting finding observed in this work, with respect to MsaB
and CcpE, is that in themsaABCR ccpE double mutant, there was still detectable capsule
production, even though it was decreased, similar to what was observed in the ccpE
mutant alone. These findings suggest that ccpEmay be epistatic tomsaB. However, this
seems to contradict our findings that MsaB represses the transcription of ccpE (Fig. 3A).
This indicates that the regulatory relationship between msaABCR, ccpE, and cap is
complex and may involve other factors. Further studies are necessary to better under-
stand these interactions.
This work focused on the nutrient-dependent regulation of capsule production in S.
aureus with respect to the nutrient-dependent regulators MsaB, CodY, and CcpE. The
findings from this work suggest that cap regulators CodY (repressor) and MsaB (acti-
vator) both directly respond to changes in nutrients within the environment of the
bacterium and, in turn, tightly control cap expression and, ultimately, the production of
capsule polysaccharide. However, many other regulators and factors are responsible for
the control of capsule production that do not have a known direct link to nutrients.
Based on previous studies and the results of this work, we propose a working model
that describes how MsaB and CodY control capsule production (Fig. 10). In this model,
we propose that under high-nutrient conditions, represented by growth in TSB broth,
CodY is bound to the cap promoter region, repressing the cap promoter (Fig. 10A).
However, as nutrients become limited, the binding affinity of CodY decreases as a result
of a conformational change in the CodY protein structure, resulting in the loss of
transcriptional repression. Under conditions in which CodY is not bound to the cap
promoter, the MsaB binding site is available, allowing MsaB to bind to and activate the
cap promoter (Fig. 10B). This proposed mechanism suggests that regulatory interac-
tions occur between CodY and MsaB as a direct response to nutrient availability. The
regulatory control of capsule production by both MsaB and CodY described in this work
MsaB and CodY Regulation of Capsule in S. aureus Journal of Bacteriology
September 2018 Volume 200 Issue 17 e00294-18 jb.asm.org 13
is representative of a mixture of incoherent feed-forward loops or (FFLs). This type of
regulatory mechanism is defined as consisting of three genes: a regulatory gene X that
regulates gene Y, and gene Z (Fig. 11A). The gene Z promoter is regulated by both X
and Y, as well as X regulating gene Z independent of Y (56, 57). In our case, MsaB
directly regulates both the cap operon (activation) and codY, which in turn regulates
capsule production. This is representative of an incoherent type 1 FFL (Fig. 11B).
Alternatively, CodY directly regulates both capsule production (repression) and msaB,
which subsequently regulates capsule production. This is representative of an incoher-
ent type 3 FFL (Fig. 11C). These regulatory interactions allow both regulators to
coordinately control the cap promoter and, ultimately, capsule production. Further-
more, the findings from this work suggest that this regulatory control of capsule
production by MsaB and CodY is dependent on the growth phase and/or nutrient
stimuli in S. aureus. Additionally, both CodY and MsaB have also been described to have
roles in the regulation of virulence, as well as MsaB possibly acting as an RNA
chaperone interacting with RNA to regulate cap and other virulence determinants in S.
aureus (7, 13, 25, 37, 42, 43, 53, 54, 58–60). Findings from this work may have
implications for the interaction of S. aureus with the host during the transition from a
FIG 10 Working model for cap operon regulation by MsaB and CodY. (A) When nutrients are abundant,
CodY binds to the CodY binding site (CBS) in the promoter region of the cap operon and represses cap
transcription. (B) When nutrient levels decrease, a conformational change in the CodY structure occurs,
resulting in a decrease in the affinity of CodY for the promoter. Detachment of CodY from the promoter
allows MsaB to access the MsaB binding site (MBS). In addition, MsaB appears to have a greater binding
ability under low nutrient levels. Binding of MsaB activates the transcription of the cap operon.
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commensal to a pathogenic form. Studies are under way to investigate whether the
described regulatory mechanism between CodY and MsaB is responsible for the
regulatory control of other virulence mechanisms possessed by S. aureus.
MATERIALS AND METHODS
Bacterial strains and growth conditions. For this study, we used S. aureus strain UAMS-1 as a
representative strain for the clinically significant capsule serotype CP8 (Table 4), as was done in our
previous study (25), and the strain USA300_LAC as a control for select transcriptional experiments (see
FIG 11 Incoherent feed-forward loops (FFLs) representing regulation of capsule production by MsaB and
CodY. (A) Examples of the four different types of incoherent FFLs are shown that describe two regulators,
“X” and “Y” (activators or repressors), controlling one gene, “Z.” (B) Highlights the incoherent type 1 FFL
with respect to MsaB regulation of capsule production, as well as the codY transcript. (C) Highlights the
incoherent type 3 FFL with respect to CodY regulation of capsule production, as well as the msaB
transcript. (B and C) Both schematics are representative of the findings described in this work with
respect to the regulation of capsule production by MsaB and CodY (cap activator and repressor,
respectively).
TABLE 4 Strains and plasmids used in this study
Strain or plasmid Relevant feature(s) Reference or source
Strains
E. coli TOP10 F 80lacZΔM15 recA1 Life Technologies
S. aureus strains
UAMS-1 CP8-producing strain
UAMS-1ΔmsaABCR msaABCR operon knockout 25
UAMS-1ΔmsaABCR comp. UAMS-1ΔmsaABCR(pCN34-msaABCR operon) 25
USA300 JE2 codY::Tn transposon mutant NARSA
USA300 JE2 ccpE::Tn transposon mutant This study
UAMS-1ΔcodY codY::Tn transposon mutant This study
UAMS-1ΔmsaABCR/ΔcodY ΔmsaABCR ΔcodY double mutant This study
UAMS-1ΔcodY 6His complement UAMS-1ΔcodY 6His(pCN34-6His-codY) This study
UAMS-1ΔmsaABCR/ΔccpE 6His complement UAMS-1ΔccpE 6His(pCN34-6His-ccpE) This study
UAMS-1ΔccpE ccpE::Tn transposon mutant This study
UAMS-1ΔmsaABCR/ΔccpE ΔmsaABCR ΔcodY double mutant This study
Plasmids
pCN34 Ampr Ermr; shuttle vector, low copy no. 25; NARSA
pCN34(Cmr)-msaABCR operon 1.7-kb PCR fragment containing msaABCR
operon cloned into pCN34(Cmr)
25, 62
pCN34(Cmr)-6His-codY codY 5= end labeled with 6His cloned into
pCN34(Cmr)
This study
This study
pCN34(Cmr)-6His-ccpE ccpE 5= end labeled with 6His cloned into
pCN34(Cmr) This study
pD861-msaB 6His-msaB protein expression vector
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Fig. S1 in the supplemental material). The restriction-deficient laboratory strain S. aureus RN4220 and
Escherichia coli strain DH5 were used to move plasmid constructs into the strains of choice through
transformation and phage transduction as described previously (58, 61, 62). S. aureus strains were
routinely grown at 37°C with shaking (250 rpm) with a flask-to-medium volume ratio of 10:1 in tryptic soy
agar (TSA) or tryptic soy broth (TSB) (Difco Laboratories, Detroit, MI) as appropriate, or for the experi-
ments with altered nutrient conditions, strains were grown at 37°C with shaking (250 rpm) with a
flask-to-medium volume ratio of 10:1 in chemically defined medium (CDM) as a nutrient-defined
medium, as described previously, with specific nutrients added (43). When required, either erythromycin
(10 g ml–1) or chloramphenicol (10 g ml–1) was added to TSB or TSA for selection. The E. coli strain was
grown at 37°C with shaking (250 rpm) in Luria-Bertani (LB) medium, with ampicillin added (100 g ml–1)
when required for selection.
Generation of transposon mutants and complementation. The codY and ccpE mutants were
generated by insertion of a transposon in the codY or ccpE ORF. Briefly, strains NE1555 (SAUSA300_1148)
(CodY) and NE1560 (SAUSA300_0658) (CcpE) were obtained from the Network on Antimicrobial Resis-
tance in Staphylococcus aureus (NARSA) collection (BEI Resources, Manassas VA). These strains contain the
bursa aurealis mariner-based erythromycin resistance expression transposon within the codY or ccpE
region, respectively. The mutations were mobilized by generalized transduction, using bacteriophage
11 (25, 60, 62), into wild-type UAMS-1. The introduction of codY::Tn and ccpE::Tn mutations was verified
by PCR, followed by sequencing and phenotypic assays (37, 39, 42–44). For trans complementation, the
codY ORF (1.4-kb codY transcript with its native promoter) or ccpE ORF, each having 6 histidine residues
at the 5= end (6His-codY or 6His-ccpE), was cloned into the pCN34 low-copy-number vector modified
by changing the kanamycin-selectable marker to a chloramphenicol resistance marker as described
previously (25, 62, 63). These complementation vectors were used in the RT-qPCR experiments and
phenotypic assays. In addition, we used these complementation vectors with the 5=-end histidine
residues (6His-codY or 6His-ccpE) to perform the chromatin immunoprecipitation (ChIP) assay.
RNA extraction, reverse transcription, and RT-qPCR. The expression of capE and msaB was
measured by RT-qPCR in the wild type, the corresponding mutants, and complemented strains. Briefly,
an aliquot of an overnight culture was normalized to an optical density of 600 nm (OD600) of 0.05 and
then grown at 37°C with shaking (250 rpm) to the appropriate growth phase. After the cells had grown
to the appropriate growth phase (early, mid-, late, or post-exponential phase), cells were pelleted by
centrifugation at 10,000  g, treated with the RNAprotect bacterial reagent (Qiagen, Valencia CA), and
stored at 80°C until analysis. For the analysis, the samples were thawed on ice and total RNA was
extracted as previously described (25, 58, 62). RNA concentration and quality were analyzed by mea-
suring absorbance and interpreting the absorbance ratio at 260 nm/280 nm using a Nanodrop spectro-
photometer (Thermo Scientific). Reverse transcription was performed with the iScript cDNA synthesis kit
(Bio-Rad Laboratories, Hercules, CA), using 1 g of the total RNA isolated according to the manufacturer’s
protocol. Next, RT-qPCR was performed using the appropriate primers (Table 5) and the relative fold
change in gene expression was calculated using gyrA, the 16S rRNA gene, and rpoB as endogenous
control genes. Fold change data represented in the main text were calculated with gyrA (Tables 1 and
3). Fold change data calculated using the 16S rRNA gene and rpoB as endogenous controls are shown
in Tables S1, S2, S5, and S6, respectively (10, 25, 58, 62). The results were consistent for all the control
genes used, and the experiments were repeated in triplicate in independent assays.
Absolute quantification of the codY and ccpE transcripts. Absolute quantification of the codY and
ccpE transcripts was performed by the method previously described by others and our previous work (25,
64). The codY and ccpE genes were amplified from chromosomal DNA using primers external to the
primers used for RT-qPCR. The PCR amplicons were purified and their concentrations were measured
using a Nanodrop spectrophotometer (Thermo Scientific). The corresponding concentrations were
converted to copies per microliter using a previously described method (65). Tenfold serial dilutions
(101 to 108) of these amplicons were used as templates for RT-qPCR. Standard curves were generated
by plotting threshold cycle (CT) values against the log of the copy numbers (log starting quantity [SQ]).
Starting quantities of “unknown” wild-type samples (early, mid-, late, and post-exponential cDNA of
UAMS-1) were calculated by plotting the respective CT values on the standard curve. Copy numbers were
measured by 10SQ. The respective copy numbers of codY or ccpE were normalized to those of gyrA (Table
2), 16S rRNA (Table S3), or rpoB (Table S4) as endogenous control genes and plotted against the standard
curve to obtain the absolute transcript copy numbers of codY or ccpE. The results were consistent for all
control genes used. The experiment was repeated in triplicate in independent assays.
In vitro capsule production assay. Total capsule production was determined using a dot blotting
method described previously (66), with the following modifications described in our previous work (25).
In brief, 2 ml of an 18-h culture, adjusted to an OD660 of 5.0, was pelleted and resuspended in 100 l of
phosphate-buffered saline (PBS). The suspension was sequentially treated with the following enzymes at
37°C: lysostaphin (100 g ml–1) for 15 min, DNase I (300 U ml–1) for 15 min, and proteinase K (100 g
ml–1) for 1 h. The proteinase K was subsequently inactivated by heating at 75°C for 10 min. The crude
capsule preparations were serially diluted and assayed by immunoblotting on a membrane using a
CP8-specific antibody as described previously (25, 66).
ChIP assays. The chromatin immunoprecipitation (ChIP) assays were performed as previously
described (67), with minor modifications as outlined in our previous work (25). Briefly, S. aureus cells were
grown to the growth phase required for a given experiment and were treated with 1% formaldehyde and
10 nM sodium phosphate to facilitate the cross-linking of the MsaB, 6His-CodY, or 6His-CcpE proteins
to their target binding sites. After 20 min, the cross-linking reaction was quenched by the addition of 0.1
volume of 3 M glycine. The cultures were subsequently washed with an equal volume of 100 mM
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phosphate buffer and pelleted by centrifugation to remove the excess formaldehyde. The cells were then
resuspended in 750 l of IP buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 5% glycerol, and 1% Triton X-100) and lysed by bead beating. The cell
debris was removed by centrifugation, and the lysate was moved into a new tube. The cell lysates were
then diluted with an additional 750 l of IP buffer, and the cellular DNA was sheared to a size of
approximately 500 bp by further bead beating. After centrifugation at 10,000  g, the supernatant was
diluted with an additional 1 ml of IP buffer. To 500 l of the cleared lysate, anti-MsaB antibody or ChIP
grade anti-His antibody (diluted 1:1,000; Abcam, Cambridge, UK) was added, and the mixture incubated
with continuous mixing at room temperature for 2 h. The antigen-antibody mixture was then added to
prewashed protein G-coupled magnetic beads (Thermo Scientific Pierce) and incubated under ambient
conditions with continuous mixing for 1 h. The antigen-antibody-bead complexes were collected with a
magnetic stand and washed, after which the antigen-antibody complexes were eluted, followed by
decoupling of the antigen-antibody complexes. After the decoupling step, the DNA was extracted using
the phenol-chloroform extraction method, followed by ethanol precipitation as previously described (25).
The DNA was used as the template to detect the MsaB-, CodY-, or CcpE-bound promoter sequences by
PCR amplification using promoter-specific primers. The msaABCR operon mutant or the codY and ccpE
mutants without the 6His-labeled complementation constructs were used as internal negative controls
to demonstrate that the antibodies specifically enriched the tested promoter region.
Altered-nutrient experiments. To observe the effect of nutrient limitation on the production of
capsule, as well as the regulatory effects of MsaB and CodY, we used a chemically defined medium (CDM)
as previously described (43). Briefly, overnight cultures grown at 37°C with shaking (250 rpm) in TSB were
diluted 1:10 in fresh, prewarmed CDM and then were incubated for an additional 2 h. Subsequently, the
cells were normalized to a OD600 of 0.05 in fresh, prewarmed CDM for use as the starter culture. These
cells were compared to cells grown under nutrient-rich growth conditions (TSB) in the early, mid-, late,
and post-exponential phases of growth. Additionally, we compared cells grown in CDM with BCAAs or
cells grown in CDM with BCAAs and then introduced into CDM without BCAAs (valine, leucine, and
isoleucine; Sigma-Aldrich, USA). Briefly, exponential cultures in the appropriate growth phase, growing
TABLE 5 Primers used in this study
Purpose and primer Sequence (5=¡3=)
Real-time PCR
RT gyrA F GCCGTCAGTCTTACCTGCTC
RT gyrA R AATAACGACACGCACACCAG
RT capE F ACATTGGTGATGTGCGTGAT
RT capE R TCACATGACGGCACTTGTTT
RT airR F TGCTGATGGTTATGAAATGA
RT airR R CATCTTGTGCCTTAGGATGT
RT airS F TTCCTAGCCAAAATGACAATA
RT airS R TTCAGTATTTGGAGACGCTAC
RT ccpE F GGGTGTTCTTCTTTGATTGG
RT ccpE R TTGAACCAACTTGCACTTGT
RT codY F ATCGCATCAAAAGTTGCAGA
RT codY R CGTGATTCAATTACACCAGCA
RT kdpD F TACCACACCATTTCAAGTTAGA
RT kdpD R GTTAAACGAGAGGATTTTTGAG
RT kdpE F AATTCAAAGTCGTTTCACAAA
RT kdpE R GAATTCATTCGGTGTTAGATG
RT rbsR F TATCGCACAATACATATCATCC
RT rbsR R GTATAGCCTTGATGGTCATTTT
RT spoVG F AGCACTCGTTTCCATTACAT
RT spoVG R TGTACGTTTACTTGGCATTG
ChIP and EMSAa
cap-ChIP F CTACTTTAGAGTATAATTATTTTTAATTTC
cap-ChIP R CCCTTAAAAATTTTCATTAAAATTG
codY-ChIP F TTTCCATGTATCTAAGCCGAG
codY-ChIP R CATCAACATATTGTGGGGTAAT
codY operon F TAAATAACACGCAATAAGTTGATTG
codY operon R CTTGAATATGATTCAATACATTTAC
ccpE-ChIP F GTAATTCAAGCTGCAGCCATG
ccpE-ChIP R TCGCTCTCTTTTCAACATGTCAC
6His-labeled complement constructs
6His-codY comp F ATCAGGGATCCATGCATCATCACCATCACCACTCAAGAAAGCGCTAACCAAG
6His-codY comp R ATGTGAATTCTTATTTACTTTTTTCTAATTCATCTAAG
6His-ccpE comp F ATCAGGGATCCATGCATCATCACCATCACCACATGATTATTGAGCATGCCCGTGA
6His-ccpE comp R ATGTGAATTCCTACGCCTTTGGTTGTTCAACAAA
aChIP, chromatin immunoprecipitation; EMSA, electrophoretic mobility shift assay.
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in CDM with BCAAs, were collected by centrifugation at 10,000  g and resuspended in CDM without
BCAAs. These cells were further incubated at 37°C with shaking (250 rpm) for an additional 30 min, after
which they were collected by centrifugation. These cells grown in CDM without BCAAs were compared
to cells grown similarly in CDM with BCAAs. Using these different nutrient conditions, we tested the
capsule phenotype, as well as the binding profile of MsaB and CodY, under different nutrient conditions.
Additionally, we observed how the change in nutrients plays a role in the regulatory interactions
between these two regulators with respect to cap.
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